In the last trading session, 2.2 million shares of the Ocular Therapeutix Inc (NASDAQ:OCUL) were traded, and its beta was 1.30. Most recently the company’s share price was $9.10, and it changed around -$0.21 or -2.26% from the last close, which brings the market valuation of the company to $1.35B. OCUL currently trades at a discount to its 52-week high of $11.31, offering almost -24.29% off that amount. The share price’s 52-week low was $2.00, which indicates that the current value has risen by an impressive 78.02% since then. We note from Ocular Therapeutix Inc’s average daily trading volume that its 10-day average is 1.48 million shares, with the 3-month average coming to 2.07 million.

Ocular Therapeutix Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.38. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 1 recommended OCUL as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Ocular Therapeutix Inc is expected to report earnings per share of -$0.17 for the current quarter.

Ocular Therapeutix Inc (NASDAQ:OCUL) trade information

Instantly OCUL has showed a red trend with a performance of -2.26% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently up 104.04% year-to-date, but still down -10.34% over the last five days. On the other hand, Ocular Therapeutix Inc (NASDAQ:OCUL) is -8.54% down in the 30-day period. We can see from the shorts that 9.16 million shares have been sold at a short interest cover period of 2.7 day(s).

The consensus price target as assigned by Wall Street analysts is $17, which translates to bulls needing to increase their stock price by 46.47% from its current value. Analyst projections state that OCUL is forecast to be at a low of $10 and a high of $24.

Ocular Therapeutix Inc (OCUL) estimates and forecasts

Ocular Therapeutix Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 186.16 percent over the past six months and at a 33.33% annual growth rate that is well above the industry average of 8.20%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 56.40% in revenue this quarter, and will report an increase of 38.50% in the next quarter. The year-over-year growth rate is expected to be 16.40%, up from the previous year.

Consensus estimates provided by 6 financial analysts predict the company will bring in an average of $15.38 million in revenue for the current quarter. 6 analysts expect Ocular Therapeutix Inc to make $16.4 million in revenue for the quarter ending Jun 2024. Analysts predict that the company’s current quarter sales will jump, forecast at 15.00%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 8.38%.

OCUL Dividends

Ocular Therapeutix Inc’s next quarterly earnings report is expected to be released around May 06 and May 10.

Ocular Therapeutix Inc (NASDAQ:OCUL)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 3.68% of Ocular Therapeutix Inc shares, and 50.11% of them are in the hands of institutional investors. The stock currently has a share float of 52.03%. Ocular Therapeutix Inc stock is held by 152 institutions, with Summer Road LLC being the largest institutional investor. By Jun 29, 2023, it held 7.71% of the shares, which is about 6.12 million shares worth $31.59 million.

Opaleye Management Inc., with 7.28% or 5.78 million shares worth $29.82 million as of Jun 29, 2023, holds the second largest percentage of outstanding shares.

Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Jun 29, 2023. The former held 2.31 million shares worth $11.93 million, making up 2.91% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 1.77 million shares worth around $6.69 million, which represents about 2.23% of the total shares outstanding.